The mutational profile of immune surveillance genes in diagnostic and refractory/relapsed DLBCLs
M Nesic, M Sønderkær, RF Brøndum, TC El-Galaly… - BMC cancer, 2021 - Springer
Background Diffuse large B-cell lymphoma (DLBCL) is the most frequent lymphoid
neoplasm among adults, and approximately 30–40% of patients will experience relapse …
neoplasm among adults, and approximately 30–40% of patients will experience relapse …
Mutational landscape of immune surveillance genes in diffuse large B-cell lymphoma
M Nesic, TC El-Galaly, M Bøgsted… - Expert review of …, 2020 - Taylor & Francis
Introduction Immune surveillance is the dynamic process whereby the immune system
identifies and kills tumor cells based on their aberrant expression of stress-related surface …
identifies and kills tumor cells based on their aberrant expression of stress-related surface …
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma,
representing∼ 30% of all cases in western countries. It is an aggressive and molecularly …
representing∼ 30% of all cases in western countries. It is an aggressive and molecularly …
Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas
Purpose: Relapsed or refractory diffuse large B-cell lymphoma (rrDLBCL) is fatal in 90% of
patients, and yet little is known about its biology. Experimental Design: Using exome …
patients, and yet little is known about its biology. Experimental Design: Using exome …
Molecular genetics of relapsed diffuse large B-cell lymphoma: insight into mechanisms of therapy resistance
MR Berendsen, WBC Stevens, M van den Brand… - Cancers, 2020 - mdpi.com
Simple Summary Many patients with the aggressive cancer diffuse large B-cell lymphoma
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …
(DLBCL) still respond poorly to treatment and suffer from relapsed or refractory disease. The …
[HTML][HTML] Mutational profile and clonal evolution of relapsed/refractory diffuse large B-cell lymphoma
Primary refractory/relapsed diffuse large B-cell lymphoma (rrDLBCL) is an unresolved issue
for DLBCL treatment and new treatments to overcome resistance is required. To explore the …
for DLBCL treatment and new treatments to overcome resistance is required. To explore the …
Single-cell transcriptome sequencing provides insight into multiple chemotherapy resistance in a patient with refractory DLBCL: a case report
K Zhao, Q Li, P Li, T Liu, X Liu, F Zhu… - Frontiers in …, 2024 - frontiersin.org
Relapsed and refractory diffuse large B-cell lymphoma (DLBCL) is associated with poor
prognosis. As such, a comprehensive analysis of intratumoral components, intratumoral …
prognosis. As such, a comprehensive analysis of intratumoral components, intratumoral …
TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era
DJ Landsburg, JJD Morrissette, SD Nasta… - Blood …, 2023 - ashpublications.org
Genetic subgroups of diffuse large B-cell lymphoma (DLBCL) have been identified through
comprehensive genomic analysis; however, it is unclear whether this can be applied in …
comprehensive genomic analysis; however, it is unclear whether this can be applied in …
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B‐cell lymphoma
S Mareschal, S Dubois, PJ Viailly… - Genes …, 2016 - Wiley Online Library
Despite the many efforts already spent to enumerate somatic mutations in diffuse large B‐
cell lymphoma (DLBCL), previous whole‐genome and whole‐exome studies conducted on …
cell lymphoma (DLBCL), previous whole‐genome and whole‐exome studies conducted on …
Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with
immunochemotherapy containing rituximab (rituximab, cyclophosphamide …
immunochemotherapy containing rituximab (rituximab, cyclophosphamide …